Neurofibromatoses - Pipeline Review, H2 2016

Neurofibromatoses - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neurofibromatoses – Pipeline Review, H2 2016, provides an overview of the Neurofibromatoses (Genetic Disorders) pipeline landscape.

Neurofibromatosis (commonly abbreviated NF; neurofibromatosis type 1 is also known as von Recklinghausen disease) is a genetically-inherited disorder in which the nerve tissue grows tumors (neurofibromas) that may be benign or may cause serious damage by compressing nerves and other tissues. The disorder affects all neural crest cells (Schwann cells, melanocytes and endoneurial fibroblasts). Cellular elements from these cell types proliferate excessively throughout the body, forming tumors; melanocytes also function abnormally in this disease, resulting in disordered skin pigmentation and café au lait spots. The tumors may cause bumps under the skin, colored spots, skeletal problems, pressure on spinal nerve roots, and other neurological problems.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neurofibromatoses – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Neurofibromatoses (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neurofibromatoses (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neurofibromatoses and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase 0, Preclinical and Discovery stages are 3, 1, 5 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Neurofibromatoses (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neurofibromatoses (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Neurofibromatoses (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neurofibromatoses (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neurofibromatoses (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neurofibromatoses (Genetic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neurofibromatoses (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neurofibromatoses (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Neurofibromatoses Overview
Therapeutics Development
Pipeline Products for Neurofibromatoses - Overview
Pipeline Products for Neurofibromatoses - Comparative Analysis
Neurofibromatoses - Therapeutics under Development by Companies
Neurofibromatoses - Therapeutics under Investigation by Universities/Institutes
Neurofibromatoses - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Neurofibromatoses - Products under Development by Companies
Neurofibromatoses - Products under Investigation by Universities/Institutes
Neurofibromatoses - Companies Involved in Therapeutics Development
Alexion Pharmaceuticals Inc
Arno Therapeutics Inc
AstraZeneca Plc
Betta Pharmaceuticals Co Ltd
Celldex Therapeutics Inc
Lixte Biotechnology Holdings Inc
Novartis AG
Plex Pharmaceuticals Inc
Neurofibromatoses - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AR-42 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
asfotase alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CDX-0158 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
everolimus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FRAX-597 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
icotinib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LB-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LB-205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OS-342 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
selumetinib sulfate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Hsp90-Alpha and TRAP1 for Neurofibromatosis Type 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Neurofibromatoses Type I - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target VEGFR1 and VEGFR2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VAL-0524 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neurofibromatoses - Dormant Projects
Neurofibromatoses - Discontinued Products
Neurofibromatoses - Product Development Milestones
Featured News & Press Releases
May 11, 2012: Arno Therapeutics Receives European Orphan Drug Designation For AR-42
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Neurofibromatoses, H2 2016
Number of Products under Development for Neurofibromatoses - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Neurofibromatoses - Pipeline by Alexion Pharmaceuticals Inc, H2 2016
Neurofibromatoses - Pipeline by Arno Therapeutics Inc, H2 2016
Neurofibromatoses - Pipeline by AstraZeneca Plc, H2 2016
Neurofibromatoses - Pipeline by Betta Pharmaceuticals Co Ltd, H2 2016
Neurofibromatoses - Pipeline by Celldex Therapeutics Inc, H2 2016
Neurofibromatoses - Pipeline by Lixte Biotechnology Holdings Inc, H2 2016
Neurofibromatoses - Pipeline by Novartis AG, H2 2016
Neurofibromatoses - Pipeline by Plex Pharmaceuticals Inc, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Neurofibromatoses - Dormant Projects, H2 2016
Neurofibromatoses - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Neurofibromatoses, H2 2016
Number of Products under Development for Neurofibromatoses - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook